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Endocrine FGF21, FGF19 and co-receptor betaKlotho
divert the roles of the canonic fibroblast growth factor
receptors (FGFRs) complex from maintaining growth/
proliferation homeostasis to local and systemic metabolic
homeostasis. These endocrine factors target adipocytes
and hepatocytes leading to alleviation of obesity, fatty
liver disease and metabolic abnormalities which are
contributing factors to the progression of several types of
tumor. Here we determined whether systemic and micro-
environmental metabolic alterations caused by FGFR4
deficiency affect tumorigenesis in breast where FGFR4 is
negligible in contrast to FGFR1. Breast tumors were
induced by overexpression of TGFa that activates
Her2 in ductal and lobular epithelium surrounded by
adipocytes. Mammary tumorigenesis and alterations in
systemic and breast microenvironmental metabolic
parameters and regulatory pathways were analyzed.
The ablation of FGFR4 had no effect on cellular home-
ostasis and Her2 activity of normal breast tissue; however,
it reduced TGFa-driven breast tumor incidence and pro-
gression and improved host survival. Notable increases in
hepatic and serum FGF21, adiponectin and adipsin, and
decreases in systemic Fetuin A, IGF-1, IGFBP-1, RBP4
and TIMP1 were observed. These alterations affected
adipogenesis and secretory function of adipocytes as well
as lipogenesis, glycolysis and energy homeostasis asso-
ciated with the functions of mitochondria, ER and peroxi-
somes in the breast and tumor foci. The ablation also
affected several pro-inflammatory factors. In line with
these data, the adipocyte-specific FGFR1 deficiency that
disrupts FGF21 signaling elevated adipose ER stress
response, and modulated the syntheses of phospholipids
and lipid mediators and lipid droplet expansion. In con-
trast, overexpression of FGF21 enhances lipolysis,
mitochondrial fatty acid oxidation and energy uncoupling,
and subdues ER stress, pro-inflammatory and oxidative
stress that maintains adipose and metabolic health. Treat-
ment with an inhibitor of NAMPT involved in the path-
ways inhibited the growth and survival of breast tumor
cells and tumor-initiating cell-containing spheres.
Although the primary role of FGFR4 in metabolism
occurs in hepatocytes, its ablation results in a net inhibi-
tory effect on mammary tumor progression, suggesting
that the tumor-delaying effect of FGFR4 deficiency may
be largely due to elevated anti-obesogenic FGF21 that
triggers stress-reducing and tumor-suppressing signals
from both peripheral and breast adipocytes. The predo-
minant changes in metabolic pathways suggested roles of
metabolic effects from both peripheral and breast adipo-
cytes on metabolic reprogramming in breast epithelial
cells that contribute to the suppression of tumor progres-
sion. These results provide new insights into the contri-
bution of systemic and microenvironmental metabolic
effects controlled by endocrine FGF signaling to breast
carcinogenesis.
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